Glioblastoma-associated microglia/macrophages (GAMs): Advances in knowledge and implications for glioblastoma (GBM) therapy
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-11 · 1881 (6) · 189742
DOI: 10.1016/j.bbcan.2026.189742 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-11. Verfasst von Siddhartha Singh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Translational Mechanobiology Laboratory, BRIC-Rajiv Gandhi Centre for Biotechnology (RGCB), Thycaud PO, Poojappura, Thiruvananthapuram 695014, Kerala…. Die Arbeit nennt 198 Literaturangaben. Gefördert von: Department of Biotechnology Ministry of Science and Technology.
Abstract (Originalsprache)
Glioblastoma (GBM) is an exceptionally aggressive, therapy-resistant central nervous system malignancy. Within the tumour microenvironment, glioblastoma-associated microglia and macrophages (GAMs) constitute a highly heterogeneous population whose functional states profoundly influence disease progression, tissue architecture, immune evasion, and treatment response. In this review, we propose a conceptual framework in which distinct GAM phenotypes emerge from the integrated influence of vascular, tumoural, metabolic, biomechanical, neural, and immune inputs, together with glyco-immune interactions, extracellular vesicles, and epigenetic regulation. As GAMs process these cues, they actively remodel their surrounding ecosystem, sustaining a protumourigenic niche. We critically evaluate emerging therapeutic interventions-including those targeting GAM abundance, immunometabolism, mechanotransduction, and intercellular communication-as well as advanced platforms such as engineered myeloid systems, phytomedicines, targeted delivery vehicles, and gut-brain axis-based strategies. Furthermore, we address key translational bottlenecks, including extreme GAM plasticity, spatial heterogeneity, limitations of preclinical models, barriers to central nervous system delivery, and a lack of predictive biomarkers. We argue that the therapeutically relevant target is not the GAM population in isolation, but rather the diverse niche-GAM functional units and the cumulative signalling networks that sustain them. Ultimately, achieving durable clinical efficacy will require biomarker-guided, spatially informed combination regimens that selectively disrupt maladaptive myeloid states while preserving physiological microglial homeostasis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Translational Mechanobiology Laboratory, BRIC-Rajiv Gandhi Centre for Biotechnology (RGCB), Thycaud PO, Poojappura, Thiruvananthapuram 695014, Kerala, India; Regional Centre for Biotechnology, Faridabad 121001, Haryana,…
Förderung
- Department of Biotechnology Ministry of Science and Technology
Zitieren
APA
Singh, S., & Mishra, R. (2026). Glioblastoma-associated microglia/macrophages (GAMs): Advances in knowledge and implications for glioblastoma (GBM) therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(6), 189742. https://doi.org/10.1016/j.bbcan.2026.189742
Vancouver
Singh S, Mishra R. Glioblastoma-associated microglia/macrophages (GAMs): Advances in knowledge and implications for glioblastoma (GBM) therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(6):189742. doi:10.1016/j.bbcan.2026.189742
BibTeX
@article{Singh2026,
author = {Singh, Siddhartha and Mishra, Rashmi},
title = {Glioblastoma-associated microglia/macrophages (GAMs): Advances in knowledge and implications for glioblastoma (GBM) therapy},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {6},
pages = {189742},
doi = {10.1016/j.bbcan.2026.189742}
}
EUVIMED